중국 CAR-T 치료 기술 수준

On March 12, 2018 the Chinese FDA (CFDA) approved the clinical trial application of LCAR-B38M CAR-T cell self-reinfusion preparation from Nanjing Legend Biotech, marking the first cellular therapy to officially enter the clinical trial stage in China.

LCAR-B38M is targeted at B-cell maturation antigen (BCMA), a member of TNF receptor family and also an extremely crucial B-cell biomarker. In multiple myeloma patients, the BCMA protein has been found on the surface of malignant plasma cells, making it an important potential therapeutic target